title: [The practice guideline 'Dermatomyositis, polymyositis and sporadic inclusion body myositis'].
abstract: This guideline presents recommendations for the diagnosis and treatment of dermatomyositis, polymyositis and sporadic inclusion body myositis (sIBM) according to the best available evidence. Characteristic skin abnormalities can be sufficient for the diagnosis of dermatomyositis. In case of doubt, a skin biopsy is advisable. A muscle biopsy is indicated when other examinations are inconclusive and the musculature is involved. The working group considers screening for cancer to be required in adults with dermatomyositis and presents recommendations for the way that this should be done. At least one-third of all patients with polymyositis has, or will develop, an associated inflammatory connective tissue disease. If a patient with a connective tissue disease develops symmetrical, proximal muscle weakness in the course of weeks or months, this may be assumed to be due to polymyositis. In the absence ofpre-existing connective tissue disease, demonstration of a mononuclear cell infiltrate in muscle tissue is a prerequisite for the diagnosis ofpolymyositis. The histopathology of muscle tissue is used as the gold standard for the diagnosis of sIBM. The practice guideline presents criteria for the concept 'activity' of myositis. Disease activity serves as a guideline for the treatment of polymyositis and dermatomyositis. The treatment of choice for dermatomyositis and polymyositis is high-dose prednisone. Physical activity does not have a negative effect on the course of these diseases. The long-term prognosis ofdermatomyositis and polymyositis is not well known. The clinical course of sIBM is slowly progressive.
authors.affiliation: Universitair Medisch Centrum Utrecht, Utrecht.
authors.forename: J E
authors.initials: JE
authors.lastname: Hoogendijk
authors.forename: J W J
authors.initials: JW
authors.lastname: Bijlsma
authors.forename: B G M
authors.initials: BG
authors.lastname: van Engelen
authors.forename: E
authors.initials: E
authors.lastname: Lindeman
authors.forename: A
authors.initials: A
authors.lastname: van Royen-Kerkhof
authors.forename: M A
authors.initials: MA
authors.lastname: de Rie
authors.forename: M
authors.initials: M
authors.lastname: de Visser
authors.forename: F G I
authors.initials: FG
authors.lastname: Jennekens
mesh_terms: D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D004305:Dose-Response Relationship, Drug; D006801:Humans; D018979:Myositis, Inclusion Body / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D009426:Netherlands; D017285:Polymyositis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D010818:Practice Patterns, Physicians'; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012955:Societies, Medical
chemical_list: D000893:Anti-Inflammatory Agents; D011241:Prednisone